PMID- 30792659
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future.
PG  - 95
LID - 10.3389/fphar.2019.00095 [doi]
LID - 95
AB  - Ocular diseases cause visual impairment and blindness, imposing a devastating 
      impact on quality of life and a substantial societal economic burden. Many such 
      diseases lack universally effective pharmacotherapies. Therefore, understanding 
      the mediators involved in their pathophysiology is necessary for the development 
      of therapeutic strategies. To this end, the hydrolase activity of soluble epoxide 
      hydrolase (sEH) has been explored in the context of several eye diseases, due to 
      its implications in vascular diseases through metabolism of bioactive 
      epoxygenated fatty acids. In this mini-review, we discuss the mounting evidence 
      associating sEH with ocular diseases and its therapeutic value as a target. 
      Substantial data link sEH with the retinal and choroidal neovascularization 
      underlying diseases such as wet age-related macular degeneration, retinopathy of 
      prematurity, and proliferative diabetic retinopathy, although some conflicting 
      results pose challenges for the synthesis of a common mechanism. sEH also shows 
      therapeutic relevance in non-proliferative diabetic retinopathy and diabetic 
      keratopathy, and sEH inhibition has been tested in a uveitis model. Various 
      approaches have been implemented to assess sEH function in the eye, including 
      expression analyses, genetic manipulation, pharmacological targeting of sEH, and 
      modulation of certain lipid metabolites that are upstream and downstream of sEH. 
      On balance, sEH inhibition shows considerable promise for treating multiple eye 
      diseases. The possibility of local delivery of inhibitors makes the eye an 
      appealing target for future sEH drug development initiatives.
FAU - Park, Bomina
AU  - Park B
AD  - Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana 
      University School of Medicine, Indianapolis, IN, United States.
AD  - Department of Pharmacology and Toxicology, Indiana University School of Medicine, 
      Indianapolis, IN, United States.
FAU - Corson, Timothy W
AU  - Corson TW
AD  - Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana 
      University School of Medicine, Indianapolis, IN, United States.
AD  - Department of Pharmacology and Toxicology, Indiana University School of Medicine, 
      Indianapolis, IN, United States.
AD  - Department of Biochemistry and Molecular Biology, Indiana University School of 
      Medicine, Indianapolis, IN, United States.
LA  - eng
GR  - R01 EY025641/EY/NEI NIH HHS/United States
GR  - TL1 TR001107/TR/NCATS NIH HHS/United States
GR  - UL1 TR001108/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20190207
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6374558
OTO - NOTNLM
OT  - age-related macular degeneration
OT  - angiogenesis
OT  - diabetic keratopathy
OT  - diabetic retinopathy
OT  - small molecule inhibitor
OT  - soluble epoxide hydrolase
OT  - uveitis
EDAT- 2019/02/23 06:00
MHDA- 2019/02/23 06:01
PMCR- 2019/02/07
CRDT- 2019/02/23 06:00
PHST- 2018/11/07 00:00 [received]
PHST- 2019/01/24 00:00 [accepted]
PHST- 2019/02/23 06:00 [entrez]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/02/23 06:01 [medline]
PHST- 2019/02/07 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00095 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Feb 7;10:95. doi: 10.3389/fphar.2019.00095. eCollection 
      2019.